AMSTERDAM (dpa-AFX) - The U.S. Food and Drug Administration has cleared the
QIAstat-Dx Respiratory Panel Plus syndromic test for clinical use, Qiagen N.V.
(QGEN) said in a statement.

The QIAstat-Dx Respiratory Panel Plus is designed to support clinical
decision-making in diagnosing upper respiratory infections and covers 21 viral
and bacterial targets. It was previously authorized under a U.S. FDA Emergency
Use Authorization.

The company noted that panel generates results in about one hour with less than
one minute of hands-on time.

The company said that it is working on expanding its portfolio for QIAstat-Dx in
the U.S., with a Gastrointestinal Panel currently under FDA review and a
Meningitis/Encephalitis Panel.

For More Such Health News, visit rttnews.com



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX